Guidance

Meningococcal B vaccine: JCVI position statement

JCVI position statement on the use of meningococcal B (MenB) vaccine in the UK.

From:
Department of Health and Social Care and Public Health England
Published
21 March 2014

Applies to England

Documents

JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK

PDF, 285 KB, 13 pages

Details

The Joint Committee on Vaccination and Immunisation (JCVI) position statement includes a recommendation to offer the Bexsero MenB vaccine to children at 2, 4 and 12 months. This recommendation depends on securing a cost effective price for the Bexsero vaccine.

The JCVI position statement sets out the results of the considerations of JCVI and its meningococcal sub-committee on the use of meningococcal B vaccine, Bexsero in the UK.

Updates to this page

Published 21 March 2014

Sign up for emails or print this page